Tubulis Announces Second Closing of Series C Bringing Total Raised to €344M (US $ 401M)

Post by: Diane De wyngaert in Press Release Tubulis
New investors Fidelity Management &…
read more
30 Oct 2025
0

Tubulis Raises €308 Million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline

Post by: Diane De wyngaert in Press Release Tubulis
• USD 361 million round…
read more
15 Oct 2025
0

Tubulis Achieves Key Milestone in BMS Strategic License Agreement as First Collaboration Tubutecan ADC Enters the Clinic

Post by: Diane De wyngaert in Press Release Tubulis
The program, licensed exclusively to…
read more
21 May 2025
0

Tubulis Doses First Patient in Phase I/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma

Post by: Diane De wyngaert in Press Release Tubulis
TUB-040 is a next-generation NaPi2b-targeting…
read more
21 Jun 2024
0

Fund+ Portfolio Company Tubulis Closes Upsized EUR 128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline

Post by: Diane De wyngaert in Press Release Tubulis
Financing round co-led by EQT…
read more
14 Mar 2024
0

Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients

Post by: Diane De wyngaert in Press Release Tubulis
Companies join forces bringing together…
read more
20 Apr 2023
0

Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies

Post by: Diane De wyngaert in Press Release Tubulis
Tubulis Closes €60 Million Series…
read more
03 May 2022
0